How often should I take BPC-157 peptide?

Last updated 2026-07-24

Is there an official dosing frequency for BPC-157?

No. There is no FDA-approved dose or dosing frequency for BPC-157 in humans, for any condition. It does not appear in the Drugs@FDA database of approved drug products, meaning it has never gone through the clinical trial process that produces an official label with dosing instructions [Drugs@FDA database]. That matters more than it sounds like it does. When a drug is FDA-approved, the frequency (once daily, twice daily, every 12 hours) comes from Phase 2 and Phase 3 trials that test multiple schedules against each other and against placebo, in hundreds or thousands of people. That process has never happened for BPC-157. What exists instead is a mix of rodent studies, a handful of small human pilot studies and case reports, and review articles that summarize the preclinical record without endorsing a specific human protocol. A 2025 literature and patent review in Pharmaceuticals covers BPC-157's proposed mechanisms and medical applications across the published record, but it is describing research findings, not a treatment protocol ^[1]. If you're looking for a validated "take X micrograms Y times a day" answer backed by human trial data, it doesn't exist yet.

How often is BPC-157 dosed in the animal studies?

Most of the foundational BPC-157 research is done in rats and mice, typically with daily or twice-daily injections given subcutaneously, intraperitoneally, or directly into an injured area, over periods ranging from about one to four weeks. This is the source of almost everything people repeat online about BPC-157 dosing. For example, the 2011 study on tendon healing in the Journal of Applied Physiology examined how BPC-157 affected tendon fibroblast outgrowth, survival, and migration in explant and in vivo models, using defined dosing regimens in that specific animal system ^[2]. A 2019 review in Cell and Tissue Research on musculoskeletal soft tissue healing summarizes multiple rodent studies where BPC-157 accelerated healing of tendon, ligament, muscle, and bone injuries, again with study-specific rodent dosing schedules ^[3]. Similarly, a 2018 paper in Current Pharmaceutical Design compares BPC-157's effects to standard angiogenic growth factors in gastrointestinal and musculoskeletal healing models ^[4], and a 2014 paper covers its proposed effects on blood vessel formation and the NO system, also in animal models ^[5]. Here's the problem with importing any of that into a human schedule: rodent metabolism, body size, and injury physiology are not human physiology. A dose or frequency that produced an effect in a 300-gram rat cannot be scaled to a 90-kg human by simple math, and nobody has published the pharmacokinetic work in humans that would let you do that conversion responsibly. A 2025 narrative review titled "Regeneration or Risk?" in Current Reviews in Musculoskeletal Medicine makes this exact point, examining the gap between preclinical promise and the absence of validated human protocols ^[6]. If you want the fuller mechanistic and dosing picture from the animal literature, our bpc 157 dosage page walks through it study by study.

What do the human studies show about dosing frequency?

The human data is small, early, and uses defined, supervised protocols rather than open-ended daily self-dosing. This is a meaningfully different picture than the rodent literature, and it's the part most vendor pages skip. A 2021 study published in Alternative Therapies in Health and Medicine looked at intra-articular (into the joint) BPC-157 injection for patients with several types of knee pain ^[7]. This was a small clinical study using a specific injection protocol delivered by a provider, not a self-administered daily regimen. A separate 2024 pilot study in the same journal examined BPC-157's effect on symptoms in patients with interstitial cystitis, again a small trial with a defined dosing course rather than indefinite daily use ^[8]. Both studies are worth naming precisely because of how small and early they are. Pilot studies and small clinical series can generate a useful signal, but they are not the large randomized controlled trials that establish a dose-response relationship or an optimal frequency. Nobody has published a dose-ranging human trial for BPC-157 comparing, say, once-daily against twice-daily against every-other-day injection to see which frequency works best. Until that trial exists, any specific frequency claim for human use is an extrapolation, not a finding.

Does BPC-157 need to be taken every day to work?

There's no published human evidence answering this directly, because no dose-frequency comparison trial exists. What the animal literature shows is that continuous dosing (daily or twice-daily) over multiple weeks is the pattern used in most rodent healing studies, which is where the assumption of "daily use" in human protocols originates. A 2025 systematic review in the HSS Journal (Hospital for Special Surgery) looked specifically at BPC-157's emerging use in orthopaedic sports medicine, pulling together the available evidence base across preclinical and limited clinical reports ^[9]. Systematic reviews like this are useful precisely because they show you the shape of the evidence, more than the results, and the shape here is: mostly animal studies with case-by-case dosing, and only a few small human reports. A 2026 primer on injectable peptide therapy for orthopaedic and sports medicine physicians, published in The American Journal of Sports Medicine, and a related 2025 Arthroscopy journal piece on injectable therapeutic peptides as an adjunct to regenerative medicine, both treat BPC-157 as an emerging, not established, therapy requiring more rigorous human dosing research before frequency questions can be answered with confidence ^{[10] [11]}. If you're trying to work out a specific number, the honest answer is that no clinical body has published one for human use.

Is there a difference in frequency for injections versus oral BPC-157?

The published clinical literature on BPC-157 (the knee and interstitial cystitis studies) used injectable administration, not oral capsules ^{[7] [8]}. Oral BPC-157 products are widely sold, but the human study record specifically documented here is injection-based, and stability and absorption through the GI tract is a separate question the peptide's discoverers have researched in animal models, distinct from proven human oral efficacy. This is a meaningful gap for anyone trying to figure out frequency. If a product is oral, dosing frequency advice from injectable research doesn't transfer cleanly, because the route of administration changes exposure entirely. Our page on BPC-157 peptide injections covers what's documented about injectable routes specifically, including the intra-articular approach used in the knee pain study ^[7].

What does a compounding pharmacy protocol actually determine?

When BPC-157 is dispensed through a licensed compounding pharmacy under a provider's evaluation, the frequency and duration on that specific prescription come from the prescribing clinician's judgment for that patient, not from an FDA label, because none exists [21 CFR 216.23] [21 U.S.C. 353a]. Compounding pharmacies operate under a distinct legal framework. Section 503A of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. 353a, allows licensed pharmacies to compound drug products for individual patients based on a valid prescription, using bulk substances that appear on FDA's 503A bulks list under 21 CFR 216.23 [21 CFR 216.23]. Larger 503B outsourcing facilities work from a separate bulks list under 21 CFR 216.24 [21 CFR 216.24]. FDA maintains its own page describing bulk drug substances nominated for compounding, and BPC-157's regulatory status there has shifted over time as the agency has evaluated safety and other statutory criteria [FDA bulk drug substances page]. The practical upshot: a prescription frequency written by a provider working with a compounding pharmacy reflects that provider's clinical judgment for your case, informed by the (still preclinical-heavy) literature, not a standardized dose validated in large trials. That's a real distinction, and it's worth understanding before you compare notes with someone else's protocol.

How long do people typically use BPC-157 before stopping?

There's no established human data on optimal treatment duration, which is a separate but related question to frequency. In the rodent literature, study durations commonly range from about 1 to 4 weeks of continuous dosing before researchers measure healing outcomes like tendon strength or wound closure ^{[3] [2]}. The small human studies used defined courses tied to the condition being studied. The intra-articular knee study followed a specific injection protocol over a set period for their patient group ^[7], and the interstitial cystitis pilot study likewise used a bounded treatment course rather than open-ended use ^[8]. Neither publication establishes a universal "correct" duration for other conditions or other people, and a 2025 review in Current Reviews in Musculoskeletal Medicine specifically flags the absence of long-term human safety and efficacy data as an open question for the field ^[6].

Does frequency change depending on what I'm using it for (injury vs. gut health)?

The animal literature covers a genuinely wide range of applications, from tendon and ligament injury to gastrointestinal healing, and the dosing schedules used in those separate lines of rodent research differ by study design, not by any established human protocol. A 2018 Current Pharmaceutical Design paper specifically compares BPC-157's actions in gastrointestinal tract healing against its actions in tendon, ligament, muscle, and bone healing, in animal models, noting overlapping mechanisms around angiogenesis ^[4]. That overlap in mechanism does not mean the human dosing frequency should be the same for a joint injury as for a gut-related use, because no human study has directly tested that comparison. A 2025 review in Pharmaceuticals covering BPC-157's proposed medical applications describes this breadth of preclinical interest across body systems, while being clear that this reflects laboratory findings, not confirmed clinical indications ^[1]. If your interest is musculoskeletal specifically, the bpc 157 peptide overview page covers what's documented across the different use cases people ask about.

What happens if I take BPC-157 too often?

There's no published human trial establishing a maximum safe frequency, which cuts both ways: it means there's no proven ceiling, but it also means there's no safety data confirming that more frequent dosing is fine. A 2026 paper in Sports Medicine reviewing the safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance treats BPC-157 among the unapproved category specifically because rigorous human safety data, including on dosing frequency limits, is still lacking ^[12]. A 2025 Arthroscopy journal piece on injectable therapeutic peptides makes a similar point about the broader category of peptides used off-label in sports medicine and regenerative practice, cautioning that enthusiasm has outpaced the safety evidence ^[11]. Anyone using a compounded product should be working with a provider who reviews frequency against their specific case, rather than following a self-designed schedule pulled from forums or product marketing. For a fuller picture of documented adverse effect reports and open safety questions, see BPC-157 peptide side effects.

Should I cycle BPC-157 (take breaks) or use it continuously?

There's no human trial comparing continuous use to cycled use, so any specific on/off schedule you see recommended is not backed by a published comparison study. The animal studies that show measurable healing effects were run over fixed windows (often 1 to 4 weeks), after which the animals were assessed and the study ended, which is different from a real-world open-ended cycling schedule ^{[3] [2]}. A 2026 paper in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews on therapeutic peptides in orthopaedics discusses the practical challenges of translating peptide research into clinical protocols, including gaps around duration and re-dosing intervals ^[13]. Until dose-ranging and duration-ranging human trials exist, decisions about cycling are matters of clinical judgment for a supervising provider, not settled science.

Where can I find dosing guidance that accounts for my body weight?

Because there's no approved human dose, any weight-based calculation you see is built from extrapolated animal dosing math, not from a validated human dose-response curve. That's a real limitation to sit with before using one. Our BPC-157 dosage calculator walks through how those extrapolations are typically built and where their assumptions come from, so you can see the math rather than just a number. If you want the full context on where injectable BPC-157 is legally sourced and how a provider-reviewed pathway works, our page on BPC-157 for sale covers that. For readers ready to move forward, working with a provider who evaluates your specific situation and coordinates with a licensed compounding pharmacy, such as the pathway BPC-157 Co outlines for its provider-reviewed dispensing, is the more accountable route than self-selecting a frequency from an online forum.

What's the bottom line on how often to take BPC-157?

The honest answer is: nobody has published the human trial that tells you. BPC-157 has never been through FDA approval, so there is no label, no approved dose, and no approved frequency [Drugs@FDA database]. Everything circulating about "twice daily" or "every other day" schedules traces back either to rodent study designs ^{[3] [2] [5]} or to small, condition-specific human pilot studies that used defined, supervised courses rather than general lifestyle dosing ^{[7] [8]}. A 2025 HSS Journal systematic review ^[9] and a 2025 narrative review in Current Reviews in Musculoskeletal Medicine ^[6] both land on the same conclusion from different angles: the preclinical signal is broad and consistent across tendon, ligament, gut, and vascular models, but the human evidence needed to set an actual frequency and duration standard is still thin. If you're considering BPC-157, that gap is the thing to take seriously, not the specific number someone posted in a comment section.

Frequently asked questions

How many times a day should I inject BPC-157?

There's no FDA-approved or clinically validated frequency for human use. Animal studies commonly use once or twice-daily dosing over several weeks, but that is rodent research, not a human protocol. Any specific daily frequency circulating online is an extrapolation from that animal data, not a finding from human trials.

Is BPC-157 approved by the FDA for any use?

No. BPC-157 does not appear in FDA's Drugs@FDA database of approved drug products, meaning it has no approved indication, dose, or frequency for any human condition. Its regulatory status as a compounded substance has also shifted over time under FDA's bulk drug substance review process.

Can I take BPC-157 every day long-term?

There's no published human study establishing safety or a recommended duration for long-term daily use. Rodent studies typically run 1 to 4 weeks. A 2025 narrative review in Current Reviews in Musculoskeletal Medicine specifically flags the lack of long-term human safety data as an open question.

Do injectable and oral BPC-157 have different dosing frequencies?

The documented human clinical studies used injectable routes (intra-articular knee injection, interstitial cystitis pilot study), not oral capsules. Since absorption differs completely by route, frequency guidance built from injectable research doesn't transfer to oral products, and there's no equivalent human trial record for oral BPC-157 specifically.

What did the human knee pain study use as a dosing schedule?

A 2021 study in Alternative Therapies in Health and Medicine examined intra-articular BPC-157 injection for multiple types of knee pain, using a defined, provider-administered protocol in a small patient group, not an open-ended self-dosing schedule. It is one of the few published human trials on BPC-157 injection.

Does BPC-157 frequency change for gut health versus injury recovery?

No human study has directly compared dosing frequency across these uses. Animal research covers both gastrointestinal healing and musculoskeletal healing with overlapping mechanisms, per a 2018 Current Pharmaceutical Design paper, but that's preclinical data, and no clinical trial has tested whether frequency should differ by use case in humans.

Is it safe to take BPC-157 more frequently if I'm not seeing results?

There's no published safety data on a maximum frequency ceiling, and no trial showing more frequent dosing improves outcomes in humans. A 2026 Sports Medicine review treats BPC-157 as an unapproved peptide with insufficient human safety data, and increasing frequency without provider oversight isn't supported by evidence.

Should I take breaks (cycle) from BPC-157?

No published human trial compares continuous dosing to cycled dosing, so any specific on/off schedule is not evidence-based. Rodent studies run fixed windows of 1 to 4 weeks and then stop for assessment. Cycling decisions are currently a matter of individual clinical judgment, not settled research.

How is BPC-157 legally dispensed if it's not FDA-approved?

Licensed compounding pharmacies can prepare BPC-157 for individual patients under a valid prescription per 21 U.S.C. 353a (Section 503A), using bulk substances FDA has evaluated for its compounding bulks list under 21 CFR 216.23. This is different from FDA drug approval and doesn't come with an official dosing label.

Can a dosage calculator tell me exactly how often to take BPC-157?

A calculator can show you weight-based math extrapolated from animal study doses, but it can't give you a validated human frequency, because that trial doesn't exist yet. Treat any calculator output as a starting reference point for a provider conversation, not a clinical prescription.

What do the systematic reviews say about BPC-157 dosing evidence overall?

A 2025 HSS Journal systematic review of BPC-157 in orthopaedic sports medicine and a 2025 narrative review in Current Reviews in Musculoskeletal Medicine both describe a preclinical-heavy evidence base with only limited, small human studies, concluding that dosing and frequency standards for human use are not yet established.

Why don't vendors just publish a standard dosing schedule?

Because none has been validated in human trials. Any schedule a vendor publishes is either drawn from animal study designs or from informal practitioner experience, not from FDA-reviewed clinical data. That's exactly why working with a provider who reviews your case individually matters more than following a generic posted protocol.

Sources

1. PubMed, Multifunctionality and Possible Medical Application of the BPC 157 Peptide (Pharmaceuticals, 2025): 2025 literature and patent review describing BPC-157's proposed mechanisms and range of preclinical medical applications
2. PubMed, Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (HSS Journal, 2025): 2025 systematic review summarizing the shape of the BPC-157 evidence base in orthopaedic sports medicine, mostly preclinical with limited human data
3. PubMed, Gastric pentadecapeptide BPC 157 and its role in accelerating musculoskeletal soft tissue healing (Cell and Tissue Research, 2019): 2019 review summarizing rodent studies on BPC-157 dosing schedules and healing effects on tendon, ligament, muscle, and bone
4. PubMed, Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain (Alternative Therapies in Health and Medicine, 2021): 2021 small human clinical study using a defined intra-articular injection protocol for knee pain patients
5. PubMed, Stable Gastric Pentadecapeptide BPC 157 and Wound Healing (Frontiers in Pharmacology, 2021): 2021 review covering BPC-157's proposed role in wound healing mechanisms
6. PubMed, BPC 157 and Standard Angiogenic Growth Factors (Current Pharmaceutical Design, 2018): 2018 paper comparing BPC-157 to angiogenic growth factors in gastrointestinal and musculoskeletal healing models in animals
7. PubMed, Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing (Current Reviews in Musculoskeletal Medicine, 2025): 2025 narrative review noting the gap between preclinical promise and lack of validated human dosing/duration protocols
8. PubMed, Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions (JAAOS Global Research & Reviews, 2026): 2026 paper discussing practical challenges translating peptide research into clinical dosing and duration protocols
9. PubMed, Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians (American Journal of Sports Medicine, 2026): 2026 physician-directed primer treating BPC-157 as an emerging therapy requiring further human dosing research
10. PubMed, Injectable Therapeutic Peptides: An Adjunct to Regenerative Medicine and Sports Performance? (Arthroscopy, 2025): 2025 review cautioning that clinical enthusiasm for injectable peptides has outpaced safety and dosing evidence
11. PubMed, The promoting effect of pentadecapeptide BPC 157 on tendon healing (Journal of Applied Physiology, 2011): 2011 study using defined rodent dosing regimens to examine tendon fibroblast outgrowth, survival, and migration
12. PubMed, Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026): 2026 review classifying BPC-157 among unapproved peptides lacking rigorous human safety and dosing-frequency data
13. PubMed, BPC 157 and blood vessels (Current Pharmaceutical Design, 2014): 2014 paper on BPC-157's proposed vascular effects in animal models
14. PubMed, Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study (Alternative Therapies in Health and Medicine, 2024): 2024 small human pilot study using a defined BPC-157 dosing course for interstitial cystitis symptoms
15. eCFR, 21 CFR 216.23, the 503A Bulk Drug Substances List: Legal basis for which bulk substances licensed compounding pharmacies may use under Section 503A
16. Cornell Law School Legal Information Institute, 21 U.S.C. 353a (Section 503A pharmacy compounding): Statutory framework allowing licensed pharmacies to compound drugs for individual patients under valid prescriptions
17. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: FDA's evaluation process and current status determinations for bulk substances nominated for compounding, including BPC-157
18. Drugs@FDA, FDA-approved drug products database: BPC-157 does not appear as an FDA-approved drug product, meaning no approved dose or frequency exists